EGFR Phosphorylates Tumor-Derived EGFRvIII Driving STAT3/5 and Progression in Glioblastoma

Cancer Cell

Volumn 24, Issue 4, 2013, Pages 438-449

  Fan, Qi Wen ^a,b   Cheng, ChristineK ^a,b   Gustafson, W Clay ^a,b   Charron, Elizabeth ^a,b   Zipper, Petra ^d,e   Wong, RobynA ^a,b   Chen, Justin ^a,b   Lau, Jasmine ^a,b   Knobbe Thomsen, Christiane ^d,e   Weller, Michael ^f   Jura, Natalia ^a   Reifenberger, Guido ^d,e   Shokat, KevanM ^a,b,c   Weiss, WilliamA ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; STAT3 PROTEIN; STAT5 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; DISEASE COURSE; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84885356671     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2013.09.004     Document Type: Article

References (32)

1. Abou-Ghazal M., Yang D.S., Qiao W., Reina-Ortiz C., Wei J., Kong L.Y., Fuller G.N., Hiraoka N., Priebe W., Sawaya R., Heimberger A.B. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin. Cancer Res. 2008, 14:8228-8235.
2. Biernat W., Huang H., Yokoo H., Kleihues P., Ohgaki H. Predominant expression of mutant EGFR (EGFRvIII) is rare in primary glioblastomas. Brain Pathol. 2004, 14:131-136.
3. Birner P., Toumangelova-Uzeir K., Natchev S., Guentchev M. STAT3 tyrosine phosphorylation influences survival in glioblastoma. J.Neurooncol. 2010, 100:339-343.
4. Bishayee A., Beguinot L., Bishayee S. Phosphorylation of tyrosine 992, 1068, and 1086 is required for conformational change of the human epidermal growth factor receptor c-terminal tail. Mol. Biol. Cell 1999, 10:525-536.
5. Bishop A.C., Ubersax J.A., Petsch D.T., Matheos D.P., Gray N.S., Blethrow J., Shimizu E., Tsien J.Z., Schultz P.G., Rose M.D., et al. A chemical switch for inhibitor-sensitive alleles of any protein kinase. Nature 2000, 407:395-401.
6. Blair J.A., Rauh D., Kung C., Yun C.H., Fan Q.W., Rode H., Zhang C., Eck M.J., Weiss W.A., Shokat K.M. Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat. Chem. Biol. 2007, 3:229-238.
7. Darnell J.E., Kerr I.M., Stark G.R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994, 264:1415-1421.
8. Doucette T.A., Kong L.Y., Yang Y., Ferguson S.D., Yang J., Wei J., Qiao W., Fuller G.N., Bhat K.P., Aldape K., et al. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012, 14:1136-1145.
9. Fan Q.W., Weiss W.A. RNA interference against a glioma-derived allele of EGFR induces blockade at G(2). Oncogene 2004, 24:829-837.
10. Fan Q.W., Cheng C.K., Nicolaides T.P., Hackett C.S., Knight Z.A., Shokat K.M., Weiss W.A. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res. 2007, 67:7960-7965.
11. Guryanova O.A., Wu Q., Cheng L., Lathia J.D., Huang Z., Yang J., MacSwords J., Eyler C.E., McLendon R.E., Heddleston J.M., et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011, 19:498-511.
12. Heimberger A.B., Hlatky R., Suki D., Yang D., Weinberg J., Gilbert M., Sawaya R., Aldape K. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res. 2005, 11:1462-1466.
13. Huang H.S., Nagane M., Klingbeil C.K., Lin H., Nishikawa R., Ji X.D., Huang C.M., Gill G.N., Wiley H.S., Cavenee W.K. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling. J.Biol. Chem. 1997, 272:2927-2935.
14. Inda M.M., Bonavia R., Mukasa A., Narita Y., Sah D.W., Vandenberg S., Brennan C., Johns T.G., Bachoo R., Hadwiger P., et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010, 24:1731-1745.
15. Johns T.G., Perera R.M., Vernes S.C., Vitali A.A., Cao D.X., Cavenee W.K., Scott A.M., Furnari F.B. The efficacy of epidermal growth factor receptor-specific antibodies against glioma xenografts is influenced by receptor levels, activation status, and heterodimerization. Clin. Cancer Res. 2007, 13:1911-1925.
16. Jura N., Endres N.F., Engel K., Deindl S., Das R., Lamers M.H., Wemmer D.E., Zhang X., Kuriyan J. Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 2009, 137:1293-1307.
17. Lo H.W., Cao X., Zhu H., Ali-Osman F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Mol. Cancer Res. 2010, 8:232-245.
18. Luwor R.B., Zhu H.J., Walker F., Vitali A.A., Perera R.M., Burgess A.W., Scott A.M., Johns T.G. The tumor-specific de2-7 epidermal growth factor receptor (EGFR) promotes cells survival and heterodimerizes with the wild-type EGFR. Oncogene 2004, 23:6095-6104.
19. McBeth L.R., St-Pierre N.R., Shoemaker D.E., Weiss W.P. Effects of transient changes in silage dry matter concentration on lactating dairy cows. J.Dairy Sci. 2013, 96:3924-3935.
20. Mellinghoff I.K., Wang M.Y., Vivanco I., Haas-Kogan D.A., Zhu S., Dia E.Q., Lu K.V., Yoshimoto K., Huang J.H., Chute D.J., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N.Engl. J. Med. 2005, 353:2012-2024.
21. Nishikawa R., Sugiyama T., Narita Y., Furnari F., Cavenee W.K., Matsutani M. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol. 2004, 21:53-56.
22. Pandita A., Aldape K.D., Zadeh G., Guha A., James C.D. Contrasting invivo and invitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004, 39:29-36.
23. Parsons J.B., Kukula M., Jackson P., Pulse M., Simecka J.W., Valtierra D., Weiss W.J., Kaplan N., Rock C.O. Perturbation of Staphylococcus aureus gene expression by the enoyl-acyl carrier protein reductase inhibitor AFN-1252. Antimicrob. Agents Chemother. 2013, 57:2182-2190.
24. Ramnarain D.B., Park S., Lee D.Y., Hatanpaa K.J., Scoggin S.O., Otu H., Libermann T.A., Raisanen J.M., Ashfaq R., Wong E.T., et al. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells. Cancer Res. 2006, 66:867-874.
25. Reardon D.A., Quinn J.A., Vredenburgh J.J., Gururangan S., Friedman A.H., Desjardins A., Sathornsumetee S., Herndon J.E., Dowell J.M., McLendon R.E., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin. Cancer Res. 2006, 12:860-868.
26. Sampson J.H., Heimberger A.B., Archer G.E., Aldape K.D., Friedman A.H., Friedman H.S., Gilbert M.R., Herndon J.E., McLendon R.E., Mitchell D.A., et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J.Clin. Oncol. 2010, 28:4722-4729.
27. Shao H., Cheng H.Y., Cook R.G., Tweardy D.J. Identification and characterization of signal transducer and activator of transcription 3 recruitment sites within the epidermal growth factor receptor. Cancer Res. 2003, 63:3923-3930.
28. Shinojima N., Tada K., Shiraishi S., Kamiryo T., Kochi M., Nakamura H., Makino K., Saya H., Hirano H., Kuratsu J., et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. 2003, 63:6962-6970.
29. Sugawa N., Ekstrand A.J., James C.D., Collins V.P. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc. Natl. Acad. Sci. USA 1990, 87:8602-8606.
30. Thiel K.W., Carpenter G. Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc. Natl. Acad. Sci. USA 2007, 104:19238-19243.
31. Weller M., Felsberg J., Hartmann C., Berger H., Steinbach J.P., Schramm J., Westphal M., Schackert G., Simon M., Tonn J.C., et al. Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. J.Clin. Oncol. 2009, 27:5743-5750.
32. Wong A.J., Ruppert J.M., Bigner S.H., Grzeschik C.H., Humphrey P.A., Bigner D.S., Vogelstein B. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl. Acad. Sci. USA 1992, 89:2965-2969.